- In April 2026, Immunovant reported that two Phase 3 GO studies of its FcRn inhibitor batoclimab in adults with active, moderate-to-severe thyroid eye disease did not meet the pre-specified primary endpoint of ≥2mm proptosis response at Week 24, though safety findings remained consistent and no new signals emerged.
- The data suggested stronger proptosis improvements during the initial high-dose period and thyroid hormone normalization in hyperthyroid patients similar to prior Graves’ disease results, prompting Immunovant to prioritize its next-generation FcRn blocker IMVT-1402 and revisit batoclimab’s future with partner HanAll Biopharma.
- We’ll now examine how batoclimab’s Phase 3 miss in thyroid eye disease could influence Immunovant’s investment narrative centered on IMVT-1402.
Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
Immunovant Investment Narrative Recap
To own Immunovant today, you need to believe that IMVT-1402 can become a meaningful FcRn therapy in large autoimmune indications, despite the company having no revenue and ongoing losses. The batoclimab TED Phase 3 miss is disappointing, but it does not directly affect the near term IMVT-1402 catalysts, with Graves’ disease data in 2027 still the key value inflection and trial execution the biggest current risk.
Among recent announcements, the April 2025 decision to expand IMVT-1402 into Sjögren’s disease and cutaneous lupus looks most relevant now, as it highlights the pipeline’s shift away from batoclimab and toward a single lead FcRn platform. In the context of the TED setback, that expansion underlines how much of the story increasingly rests on IMVT-1402 delivering across multiple autoimmune settings.
Yet against that promise, the risk that IMVT-1402 trial timelines slip or effect sizes underwhelm is something investors should be aware of if...
Read the full narrative on Immunovant (it's free!)
Immunovant's narrative projects $381.4 million revenue and $47.7 million earnings by 2029. This requires an earnings increase of about $512 million from -$464.2 million today.
Uncover how Immunovant's forecasts yield a $41.12 fair value, a 68% upside to its current price.
Exploring Other Perspectives
Before this TED setback, the most optimistic analysts were modeling about US$520.0 million of revenue and US$56.6 million of earnings by 2029, which is far more ambitious than the baseline view and could look very different once the impact of a key trial failure on that best in class IMVT-1402 thesis becomes clearer.
Explore 2 other fair value estimates on Immunovant - why the stock might be worth just $40.12!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Immunovant research is our analysis highlighting 3 important warning signs that could impact your investment decision.
- Our free Immunovant research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunovant's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com